Phase II Trial of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

Trial Profile

Phase II Trial of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2016

At a glance

  • Drugs Selumetinib (Primary)
  • Indications Neurofibromatoses; Plexiform neurofibroma
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Jan 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Jun 2019, as reported by ClinicalTrials.gov.
    • 05 Jan 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Jun 2019, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top